Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of TQ05105 + TQB3909 in intermediate- or high-risk myelofibrosis
CTR20240366Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rovadicitinib, TQB3909 in myelofibrosis (MF), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2024; status: terminated.
02
Drugs
rovadicitinibTQB3909
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20240366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240366.